Core Insights - EDAP TMS SA has appointed Glen French to its Board of Directors, enhancing its leadership with his extensive experience in medical devices and technology [1][2][4] - Glen French emphasizes the transformative potential of EDAP's Focal One technology in treating prostate cancer and its applicability to other medical conditions [2][3] Company Overview - EDAP TMS SA is a leader in robotic energy-based therapies, focusing on minimally invasive medical devices utilizing ultrasound technology [5] - The Focal One platform is recognized as a leading prostate focal therapy, with potential expansion into other therapeutic areas [5] Leadership Background - Glen French has over 25 years of experience in the medical device industry, having co-founded and sold three companies and taken another public [2][3] - He served as CEO of Pulmonx Corporation, achieving over 20% compound annual revenue growth and successfully executing an IPO that raised $218.5 million [2][3] Strategic Direction - The addition of Glen French to the Board is expected to guide EDAP's strategic decision-making as it aims to establish Focal One as the premier robotic HIFU technology platform [2] - French believes that the technology can address significant unmet medical needs across various patient populations, indicating a broad market potential [2][3]
EDAP Appoints Glen French to Board of Directors